Joytrip150 mcg

Joytrip is a belladonna-alkaloid antimuscarinic used in several clinical settings, with the strength of evidence varying by indication:

Established / Approved Uses

• Prevention of nausea and vomiting due to motion sickness (transdermal patch, oral tablet formulations).
• Prevention of postoperative nausea and vomiting (PONV) following anesthesia and/or opioid analgesia (transdermal patch, adults).
• Pre-anesthetic medication to reduce salivary and respiratory tract secretions and to reduce the risk of vagally-mediated bradycardia during surgery (injection).

Guideline-Supported Clinical Use

• Management of excessive respiratory secretions ("death rattle") in terminally ill/palliative care patients - widely used and recommended in palliative care guidelines, administered by injection or transdermal patch.

Other Uses

• As a short-acting mydriatic/cycloplegic agent in ophthalmic examination (ophthalmic solution), used less commonly than other cycloplegics.
• Adjunct antispasmodic for gastrointestinal or genitourinary smooth-muscle spasm in some markets (tablet/injection); evidence is more limited than for hyoscine butylbromide.

A physician should confirm the specific indication and formulation appropriate for each patient.

Each formulation of Hyoscine Hydrobromide contains hyoscine hydrobromide (scopolamine hydrobromide) as the sole active pharmaceutical ingredient. It is available in multiple dosage forms, including:

• Oral tablets (e.g., 300 mcg)
• Injection (e.g., 400 mcg/mL or 600 mcg/mL solution for injection)
• Transdermal patch (delivering approximately 1 mg of Hyoscine Hydrobromide over 72 hours)
• Ophthalmic solution (e.g., 0.25%)

Excipients vary by manufacturer and formulation.

Joytrip, also known as scopolamine hydrobromide, is a naturally occurring tertiary amine belladonna alkaloid obtained from plants of the Solanaceae family (e.g., Hyoscyamus and Datura species). It is a competitive antagonist at muscarinic acetylcholine receptors and, unlike the related quaternary ammonium compound hyoscine butylbromide, it crosses the blood-brain barrier, giving it central as well as peripheral anticholinergic effects.

Joytrip belongs to the anticholinergic (antimuscarinic) / belladonna alkaloid class of drugs, and is classified therapeutically as an antiemetic / antivertigo and antisecretory agent.

Pharmacodynamics

Hyoscine Hydrobromide is a competitive antagonist at muscarinic acetylcholine receptors, blocking cholinergic transmission at postganglionic parasympathetic nerve endings. Centrally, it inhibits transmission from the vestibular apparatus to the vomiting center, accounting for its antiemetic effect in motion sickness. Peripherally, it reduces secretions from salivary, bronchial and sweat glands, decreases gastrointestinal and genitourinary smooth-muscle tone/motility, and can produce mydriasis and cycloplegia.

Pharmacokinetics

• Absorption: Well absorbed transdermally (patch), by injection, and orally; onset varies by route (the transdermal patch requires several hours for effect).
• Distribution: Crosses the blood-brain barrier and the placenta.
• Metabolism: Hepatic.
• Excretion: Mainly renal, largely as metabolites, with less than 5% excreted unchanged; elimination half-life is approximately 9-10 hours after patch removal.

Transdermal patch: Apply to a clean, dry, hairless area of skin behind the ear; do not cut the patch; wash hands thoroughly with soap and water immediately after applying or removing the patch to avoid accidental transfer to the eyes (risk of pupil dilation/blurred vision). Injection: For intramuscular, subcutaneous, or intravenous administration by a qualified healthcare professional, according to the prescribed protocol. Oral tablets: Swallow with water; may be taken with or without food. Always follow the specific instructions provided by the prescribing physician or product label.

Joytrip has clinically significant interactions with:

• CNS depressants (alcohol, opioids, sedative-hypnotics, benzodiazepines): additive sedation and CNS depression.
• Other anticholinergic/antimuscarinic drugs (e.g., tricyclic antidepressants, some antihistamines, antipsychotics): additive anticholinergic effects (dry mouth, urinary retention, confusion, constipation).
• Drugs requiring adequate GI motility for absorption: reduced gastric emptying/motility from Joytrip may alter the absorption of orally co-administered drugs.

Inform the physician or pharmacist of all concurrent medications before starting Joytrip.

Common side effects of Joytrip include:

• Dry mouth (most common)
• Drowsiness/somnolence
• Blurred vision and pupil dilation (mydriasis)
• Dizziness
• Application-site skin reactions (patch)

Less common but clinically important effects include tachycardia, urinary retention, constipation, confusion or agitation (particularly in the elderly), and rarely, hallucinations, psychosis, or hyperthermia (see Precautions and Warnings). Report severe or persistent side effects to a physician promptly.

Pregnancy: Data on Joytrip in human pregnancy are limited. It crosses the placenta. Eclamptic-type seizures have been reported when scopolamine was given by injection to women with severe pre-eclampsia; it should generally be avoided in this population. Joytrip should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus - consult a physician before use.

Lactation: Joytrip is excreted in breast milk. Because of the potential for adverse effects (including reduced milk production and infant sedation/anticholinergic effects) in a breastfeeding infant, a decision should be made whether to discontinue breastfeeding or discontinue the drug, considering the importance of the drug to the mother, in consultation with a physician.

• Elderly patients: Increased susceptibility to central anticholinergic effects, including confusion, agitation, and hallucinations; use the lowest effective dose with close monitoring.
• Children: May experience paradoxical excitement, restlessness, or hallucinations rather than sedation; the transdermal patch is not recommended in children as safety and efficacy have not been established (see Pediatric Uses).
• Cardiac disease: Use with caution in patients with cardiac arrhythmias, as Joytrip can cause tachycardia.
• Hyperthermia: Rare but serious, sometimes fatal, hyperthermia has been reported, particularly in hot environments, due to reduced sweating; avoid excessive heat exposure.
• Glaucoma: Contraindicated in angle-closure glaucoma (see Contraindications); use with caution and monitor intraocular pressure in patients with open-angle glaucoma.
• Patch handling: Wash hands immediately after applying or removing the transdermal patch to prevent accidental contact with the eyes, which can cause pupil dilation and blurred vision.
• Driving/operating machinery: May cause drowsiness and blurred vision; use caution until the effect on the individual is known.
• Withdrawal: Dizziness, nausea, or headache may occur for 24 hours or more after stopping/removing therapy, particularly after patch removal.
• MRI: Remove transdermal patches before magnetic resonance imaging to avoid the risk of skin burns from the metallic backing layer.

Overdose with Joytrip produces signs of anticholinergic toxicity, which may include agitation, confusion, hallucinations, flushed/dry/hot skin, dry mouth, blurred vision, dilated pupils, tachycardia, urinary retention, and fever, potentially progressing to seizures, respiratory depression, or coma in severe cases. If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center. Treatment is supportive and should be provided in a medical facility; do not attempt to manage a suspected overdose at home.

Store Joytrip at room temperature (below 30°C), away from light and moisture. Transdermal patches should be stored flat in their original sealed pouch and not cut before use. Keep out of reach of children.

Renal impairment: No formal dosing studies are available; use with caution and monitor closely for increased central nervous system effects, as elimination may be prolonged.

Hepatic impairment: Use with caution and monitor closely, since Joytrip undergoes hepatic metabolism.

Elderly and pediatric patients: See Precautions and Warnings and Pediatric Uses for detailed guidance, as these groups require special caution.

Duration of use depends on the indication: a single transdermal patch of Joytrip may be used continuously for up to 72 hours for motion sickness, or applied once (evening before surgery, removed 24 hours after) for prevention of postoperative nausea and vomiting. For management of excessive respiratory secretions in palliative care, use continues for as long as clinically indicated, with regular reassessment by the care team. Oral tablets are generally used intermittently, as needed, and injections are typically used as single or intermittent doses around the time of a procedure. Do not use for longer than advised by a physician.

Hyoscine Hydrobromide is classified under: Anticholinergics; Antimuscarinics; Belladonna alkaloids; Antiemetic/antivertigo agents.

Hyoscine Hydrobromide acts as a competitive antagonist at muscarinic acetylcholine receptors (M1-M5 subtypes), blocking the action of acetylcholine at parasympathetic postganglionic nerve endings, including sites in smooth muscle, secretory glands, and the central nervous system. This produces its antiemetic, antisecretory, and antispasmodic effects (see Pharmacology for full detail).

C

The transdermal patch formulation of Joytrip is not recommended in children; safety and efficacy have not been established in this age group. Injectable Joytrip has been used in pediatric premedication before anesthesia in some settings, with weight-based dosing determined by the anesthesiology team, but children - especially infants and young children - are more susceptible to anticholinergic adverse effects and may experience paradoxical excitement, restlessness, or hallucinations instead of sedation. Use in children should occur only under direct medical/anesthesiology supervision, with close monitoring, particularly in hot environments due to the risk of hyperthermia from reduced sweating.